Physician profile
Kerry Chamberlain
NPI 1073502233
$5,689.77
in general payments reported to CMS, 2019-2025
52 companies · $1,183 in 2025
The $1,183 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $123 · 2021: $169 · 2022: $636 · 2023: $1,322 · 2024: $1,795 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,294 · Education: $6.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,293.85 |
| Education | $6.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,214.23 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $698.52 | 2019-2025 | |
| Gilead Sciences, INC. | $374.64 | 2021-2025 | Trodelvy |
| Abbvie INC. | $369.68 | 2022-2025 | Venclexta |
| Pfizer INC. | $367.46 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $288.01 | 2019-2025 | Reblozyl, Opdivo |
| Merck Sharp & Dohme LLC | $221.68 | 2019-2025 | Keytruda, Lynparza |
| Array Biopharma INC | $176.55 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Daiichi Sankyo INC. | $140.47 | 2023-2024 | Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $125.73 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Incyte Corporation | $110.85 | 2021-2022 | |
| Astellas Pharma US INC | $92.59 | 2019-2025 | Padcev, Xospata |
| Janssen Biotech, INC. | $90.02 | 2022-2025 | Darzalex, Erleada |
| Intuitive Surgical, INC. | $86.61 | 2019 | |
| Eisai INC. | $80.83 | 2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Chamberlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.